Cargando…
SWI/SNF aberrations sensitize pancreatic cancer cells to DNA crosslinking agents
While gemcitabine has been the mainstay therapy for advanced pancreatic cancer, newer combination regimens (e.g. FOLFIRINOX) have extended patient survival, though carry greater toxicity. Biomarkers are needed to better stratify patients for appropriate therapy. Previously, we reported that one-thir...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839388/ https://www.ncbi.nlm.nih.gov/pubmed/29515757 http://dx.doi.org/10.18632/oncotarget.20033 |